New results show sustained efficacy with secukinumab over one year in psoriatic arthritis patients
29 June 2015 | By Victoria White
New one year results from the pivotal Phase III FUTURE 2 study of Novartis’ secukinumab in psoriatic arthritis (PsA) have been published.